Veracyte, Inc. – NASDAQ:VCYT
Founder-led company
Veracyte stock price today
$30.22
-9.89
-24.68%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Veracyte stock price monthly change
+76.35%
month
Veracyte stock price quarterly change
+76.35%
quarter
Veracyte stock price yearly change
+41.12%
year
Veracyte key metrics
Market Cap | 3.11B |
Enterprise value | 1.39B |
P/E | -41.94 |
EV/Sales | 4.69 |
EV/EBITDA | -134.94 |
Price/Sales | 5.16 |
Price/Book | 1.42 |
PEG ratio | -0.65 |
EPS | -0.94 |
Revenue | 375.47M |
EBITDA | 50.46M |
Income | -68.17M |
Revenue Q/Q | 17.49% |
Revenue Y/Y | 20.66% |
Profit margin | -12.33% |
Oper. margin | -13.85% |
Gross margin | 74.6% |
EBIT margin | -13.85% |
EBITDA margin | 13.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVeracyte stock price history
Veracyte stock forecast
Veracyte financial statements
Average Price Target
$35
Potential upside: 15.81%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 90.32M | -8.40M | -9.3% |
|---|---|---|---|
| Sep 2023 | 90.10M | -29.61M | -32.87% |
| Dec 2023 | 98.19M | -28.29M | -28.81% |
| Mar 2024 | 96.84M | -1.86M | -1.92% |
| Jun 2023 | 1161114000 | 78.39M | 6.75% |
|---|---|---|---|
| Sep 2023 | 1124943000 | 70.88M | 6.3% |
| Dec 2023 | 1137821000 | 93.71M | 8.24% |
| Mar 2024 | 1200073000 | 81.42M | 6.78% |
| Jun 2023 | 16.67M | -3.66M | 397K |
|---|---|---|---|
| Sep 2023 | 14.17M | -2.80M | 110K |
| Dec 2023 | 15.55M | -2.49M | 645K |
| Mar 2024 | -8.96M | 2.87M | -864K |
Veracyte alternative data
| Aug 2023 | 787 |
|---|---|
| Sep 2023 | 787 |
| Oct 2023 | 787 |
| Nov 2023 | 787 |
| Dec 2023 | 787 |
| Jan 2024 | 787 |
| Feb 2024 | 787 |
| Mar 2024 | 815 |
| Apr 2024 | 815 |
| May 2024 | 815 |
| Jun 2024 | 815 |
| Jul 2024 | 815 |
Veracyte other data
97.78%
-2.22%
of VCYT is owned by hedge funds
187
-2
69.88M
-7.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 10000 |
| Apr 2024 | 0 | 10000 |
| May 2024 | 0 | 1539 |
| Jun 2024 | 0 | 10240 |
| Jul 2024 | 0 | 13777 |
| Aug 2024 | 0 | 64839 |
| Sep 2024 | 0 | 10652 |
| Nov 2024 | 0 | 50038 |
| Dec 2024 | 0 | 37229 |
| Patent |
|---|
Application Filling date: 16 Jun 2021 Issue date: 12 May 2022 |
Application Filling date: 21 Dec 2021 Issue date: 14 Apr 2022 |
Application Filling date: 26 Jun 2020 Issue date: 17 Mar 2022 |
Application Filling date: 30 Mar 2021 Issue date: 18 Nov 2021 |
Application Filling date: 30 Mar 2021 Issue date: 28 Oct 2021 |
Application Filling date: 30 Mar 2021 Issue date: 21 Oct 2021 |
Application Filling date: 30 Mar 2021 Issue date: 26 Aug 2021 |
Application Filling date: 25 Jan 2021 Issue date: 5 Aug 2021 |
Application SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSIS ON TRANSBRONCHIAL BIOPSIES USING MACHINE LEARNING AND HIGH DIMENSIONAL TRANSCRIPTIONAL DATA Filling date: 3 Apr 2020 Issue date: 18 Mar 2021 |
Grant Filling date: 13 Jan 2014 Issue date: 2 Mar 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Veracyte stock today?
One share of Veracyte stock can currently be purchased for approximately $30.22.
-
When is Veracyte's next earnings date?
Unfortunately, Veracyte's (VCYT) next earnings date is currently unknown.
-
Does Veracyte pay dividends?
No, Veracyte does not pay dividends.
-
How much money does Veracyte make?
Veracyte has a market capitalization of 3.11B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.76% to 361.05M US dollars.
-
What is Veracyte's stock symbol?
Veracyte, Inc. is traded on the NASDAQ under the ticker symbol "VCYT".
-
What is Veracyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Veracyte?
Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Veracyte's key executives?
Veracyte's management team includes the following people:
- Ms. Bonnie H. Anderson Co-Founder & Executive Chairwoman(age: 67, pay: $1,250,000)
- Dr. Giulia C. Kennedy Ph.D. Chief Scientific & Medical Officer(age: 66, pay: $703,000)
- Mr. John Walter Hanna Jr. Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma(age: 44, pay: $622,000)
- Dr. Tina S. Nova Ph.D. Gen. Mang. of Thyroid & Urologic Cancers(age: 71, pay: $53,330)
-
Is Veracyte founder-led company?
Yes, Veracyte is a company led by its founder Ms. Bonnie H. Anderson.
-
How many employees does Veracyte have?
As Jul 2024, Veracyte employs 815 workers.
-
When Veracyte went public?
Veracyte, Inc. is publicly traded company for more then 11 years since IPO on 30 Oct 2013.
-
What is Veracyte's official website?
The official website for Veracyte is veracyte.com.
-
Where are Veracyte's headquarters?
Veracyte is headquartered at 6000 Shoreline Court, South San Francisco, CA.
-
How can i contact Veracyte?
Veracyte's mailing address is 6000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +65 02436300.
-
What is Veracyte stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Veracyte in the last 12 months, the avarage price target is $35. The average price target represents a 15.81% change from the last price of $30.22.
Veracyte company profile:
Veracyte, Inc.
veracyte.comExchange:
NASDAQ
Full time employees:
815
Industry:
Biotechnology
Sector:
Healthcare
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
6000 Shoreline Court
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0001384101
ISIN: US92337F1075
CUSIP: 92337F107
